A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give ABT-378/ritonavir
combination plus nevirapine plus two nucleoside transcriptase inhibitors to HIV-infected
patients who previously have taken protease inhibitors. This study also examines how the body
handles this combination of anti-HIV drugs.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
Treatments:
HIV Protease Inhibitors Lopinavir Nevirapine Protease Inhibitors Ritonavir